Cover Image
Market Research Report

Overactive Bladder Therapeutics Market by Product and Geography - Global Forecast and Analysis 2019-2023

Published by TechNavio (Infiniti Research Ltd.) Product code 907875
Published Content info 157 Pages
Delivery time: 1-2 business days
Price
Back to Top
Overactive Bladder Therapeutics Market by Product and Geography - Global Forecast and Analysis 2019-2023
Published: August 21, 2019 Content info: 157 Pages
Description

About this market

Technavio's overactive bladder (OAB) therapeutics market analysis considers sales from anticholinergics. Beta-3 adrenergic agonists, and other OAB therapeutics. Our analysis also considers the sales of overactive bladder therapeutics in Asia, Europe, North America, and ROW. In 2018, the anticholinergics segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as increasing availability of branded drugs and rise in popularity of combination therapy will play a significant role in the anticholinergics segment to maintain its market position. Also, our global overactive bladder therapeutics market report looks at factors such as the increasing number of drug approvals, the advent of combination therapy, and strategic alliance. However, extensive use devices to treat OAB, side effects associated with OAB, and rising patent litigations may hamper the growth of the overactive bladder therapeutics industry over the forecast period.

Overview

The advent of combination therapy

The launch of combination therapy offers patients an efficacious pharmacological regime which requires shorter duration for treatment and reduces the overall cost associated with medication treatment. Astellas was the first vendor to introduce a combination therapy, which exhibits higher efficacy with fewer side-effects. This advent of combination therapy will lead to the expansion of the global overactive bladder therapeutics market at a CAGR of almost 2% during the forecast period.

The advent of gene therapy

The treatment therapy available for OAB involves the use of small molecules, which helps in the relaxation of smooth muscles in the urinary bladder to control the emptying of the bladder. The medication therapy, which is used exerts its pharmacological effect by suppressing the overactivity of the detrusor muscle. The drugs used in the therapy are associated with certain side effects like dry mouth, constipation, blurred vision, and cognitive impairment. Thus, there is a need for the development of biological drugs targeting the gene and consequently improving bladder functioning. The ongoing research in this area is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global overactive bladder therapeutics market during the forecast period 2019-2023, view our report.

Competitive Landscape

With the presence of several major players, the global overactive bladder therapeutics market is moderately fragmented. Technavio's robust vendor analysis is designed to help clients improve their market position. This report provides a detailed analysis of several leading overactive bladder therapeutics manufacturers, that include AbbVie Inc., Astellas Pharma Inc., Camber Pharmaceuticals Inc., Endo International Plc., KYORIN Holdings Inc., Merck & Co. Inc., Mylan NV, Ono Pharmaceutical Co. Ltd., Pfizer Inc., Teva Pharmaceutical Industries Ltd.

Also, the overactive bladder therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

Table of Contents
Product Code: IRTNTR31920

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: PIPELINE LANDSCAPE

PART 07: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Anticholinergics - Market size and forecast 2018-2023
  • Beta-3 adrenergic agonists - Market size and forecast 2018-2023
  • Other OAB therapeutics - Market size and forecast 2018-2023
  • Market opportunity by product

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 12: MARKET TRENDS

  • Advent of gene therapy
  • Rising risk factors of OAB
  • Growing geriatric population

PART 13: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 14: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AbbVie Inc.
  • Astellas Pharma, Inc.
  • Camber Pharmaceuticals Inc.
  • Endo International Plc
  • KYORIN Holdings Inc.
  • Merck & Co., Inc.
  • Mylan NV
  • Ono Pharmaceutical Co. Ltd.
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.

PART 15: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 16: EXPLORE TECHNAVIO

LIST OF EXHIBITS:

  • Exhibit 01: Vendors: Key offerings
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Segments of global pharmaceuticals market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Some key clinical trials in global OAB therapeutics market
  • Exhibit 19: Product - Market share 2018-2023 (%)
  • Exhibit 20: Comparison by product
  • Exhibit 21: Anticholinergics - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 22: Anticholinergics - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: Beta-3 adrenergic agonists - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 24: Beta-3 adrenergic agonists - Year-over-year growth 2019-2023 (%)
  • Exhibit 25: Other OAB therapeutics - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 26: Other OAB therapeutics - Year-over-year growth 2019-2023 (%)
  • Exhibit 27: Market opportunity by product
  • Exhibit 28: Customer landscape
  • Exhibit 29: Market share by geography 2018-2023 (%)
  • Exhibit 30: Geographic comparison
  • Exhibit 31: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 32: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 33: Top 3 countries in North America
  • Exhibit 34: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 35: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 36: Top 3 countries in Europe
  • Exhibit 37: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 38: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 39: Top 3 countries in Asia
  • Exhibit 40: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 41: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 42: Top 3 countries in ROW
  • Exhibit 43: Key leading countries
  • Exhibit 44: Market opportunity
  • Exhibit 45: Impact of drivers and challenges
  • Exhibit 46: Vendor landscape
  • Exhibit 47: Landscape disruption
  • Exhibit 48: Vendors covered
  • Exhibit 49: Vendor classification
  • Exhibit 50: Market positioning of vendors
  • Exhibit 51: AbbVie Inc. - Vendor overview
  • Exhibit 52: AbbVie Inc. - Business segments
  • Exhibit 53: AbbVie Inc. - Organizational developments
  • Exhibit 54: AbbVie Inc. - Geographic focus
  • Exhibit 55: AbbVie Inc. - Key offerings
  • Exhibit 56: AbbVie Inc. - Key customers
  • Exhibit 57: Astellas Pharma Inc. - Vendor overview
  • Exhibit 58: Astellas Pharma Inc. - Business segments
  • Exhibit 59: Astellas Pharma Inc. - Organizational developments
  • Exhibit 60: Astellas Pharma Inc. - Geographic focus
  • Exhibit 61: Astellas Pharma Inc. - Key offerings
  • Exhibit 62: Astellas Pharma Inc. - Key customers
  • Exhibit 63: Camber Pharmaceuticals Inc. - Vendor overview
  • Exhibit 64: Camber Pharmaceuticals Inc. - Business segments
  • Exhibit 65: Camber Pharmaceuticals Inc. - Organizational developments
  • Exhibit 66: Camber Pharmaceuticals Inc. - Key offerings
  • Exhibit 67: Camber Pharmaceuticals Inc. - Key customers
  • Exhibit 68: Endo International Plc - Vendor overview
  • Exhibit 69: Endo International Plc - Business segments
  • Exhibit 70: Endo International Plc - Organizational developments
  • Exhibit 71: Endo International Plc - Geographic focus
  • Exhibit 72: Endo International Plc - Segment focus
  • Exhibit 73: Endo International Plc - Key offerings
  • Exhibit 74: Endo International Plc - Key customers
  • Exhibit 75: KYORIN Holdings Inc. - Vendor overview
  • Exhibit 76: KYORIN Holdings Inc. - Business segments
  • Exhibit 77: KYORIN Holdings Inc. - Organizational developments
  • Exhibit 78: KYORIN Holdings Inc. - Geographic focus
  • Exhibit 79: KYORIN Holdings Inc. - Segment focus
  • Exhibit 80: KYORIN Holdings Inc. - Key offerings
  • Exhibit 81: KYORIN Holdings Inc. - Key customers
  • Exhibit 82: Merck & Co. Inc. - Vendor overview
  • Exhibit 83: Merck & Co. Inc. - Business segments
  • Exhibit 84: Merck & Co. Inc. - Organizational developments
  • Exhibit 85: Merck & Co. Inc. - Geographic focus
  • Exhibit 86: Merck & Co. Inc. - Segment focus
  • Exhibit 87: Merck & Co. Inc. - Key offerings
  • Exhibit 88: Merck & Co. Inc. - Key customers
  • Exhibit 89: Mylan NV - Vendor overview
  • Exhibit 90: Mylan NV - Product segments
  • Exhibit 91: Mylan NV - Organizational developments
  • Exhibit 92: Mylan NV - Geographic focus
  • Exhibit 93: Mylan NV - Segment focus
  • Exhibit 94: Mylan NV - Key offerings
  • Exhibit 95: Mylan NV - Key customers
  • Exhibit 96: Ono Pharmaceutical Co. Ltd. - Vendor overview
  • Exhibit 97: Ono Pharmaceutical Co. Ltd. - Business segments
  • Exhibit 98: Ono Pharmaceutical Co. Ltd. - Organizational developments
  • Exhibit 99: Ono Pharmaceutical Co. Ltd. - Geographic focus
  • Exhibit 100: Ono Pharmaceutical Co. Ltd. - Key offerings
  • Exhibit 101: Ono Pharmaceutical Co. Ltd. - Key customers
  • Exhibit 102: Pfizer Inc. - Vendor overview
  • Exhibit 103: Pfizer Inc. - Business segments
  • Exhibit 104: Pfizer Inc. - Organizational developments
  • Exhibit 105: Pfizer Inc. - Geographic focus
  • Exhibit 106: Pfizer Inc. - Segment focus
  • Exhibit 107: Pfizer Inc. - Key offerings
  • Exhibit 108: Pfizer Inc. - Key customers
  • Exhibit 109: Teva Pharmaceutical Industries Ltd. - Vendor overview
  • Exhibit 110: Teva Pharmaceutical Industries Ltd. - Business segments
  • Exhibit 111: Teva Pharmaceutical Industries Ltd. - Organizational developments
  • Exhibit 112: Teva Pharmaceutical Industries Ltd. - Segment focus
  • Exhibit 113: Teva Pharmaceutical Industries Ltd. - Key offerings
  • Exhibit 114: Teva Pharmaceutical Industries Ltd. - Key customers
  • Exhibit 115: Validation techniques employed for market sizing
  • Exhibit 116: Definition of market positioning of vendors
Back to Top